Similar articles

• Postmarketing evidence of disease-modifying drugs in multiple sclerosis.

  Trojano M, Paolicelli D, Fuiani A, Pellegrini F, Iaffaldano P, Direnzo V, D'Onghia M. Trojano M, et al. Neurol Sci. 2008 Sep;29 Suppl 2:S225-6. doi: 10.1007/s10072-008-0944-z. Neurol Sci. 2008. PMID: 18690499 Review.
• Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?

  Wilkins DE. Wilkins DE. Neurology. 2008 Aug 5;71(6):463; author reply 463-4. doi: 10.1212/01.wnl.0000330415.98748.71. Neurology. 2008. PMID: 18678834 No abstract available.
• The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis.

  Trojano M, Russo P, Fuiani A, Paolicelli D, Di Monte E, Granieri E, Rosati G, Savettieri G, Comi G, Livrea P; MSDN Study Group. Trojano M, et al. Mult Scler. 2006 Oct;12(5):578-85. doi: 10.1177/1352458506070620. Mult Scler. 2006. PMID: 17086903
• How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

  Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS. Brown MG, et al. Neurology. 2007 Oct 9;69(15):1498-507. doi: 10.1212/01.wnl.0000271884.11129.f3. Epub 2007 Aug 15. Neurology. 2007. PMID: 17699802
• What can be learned from open direct comparative trials in multiple sclerosis?

  Khan O. Khan O. J Neurol Sci. 2009 Feb 1;277 Suppl 1:S25-8. doi: 10.1016/S0022-510X(09)70008-5. J Neurol Sci. 2009. PMID: 19200861 Review.